12/19
01:13 pm
ibrx
Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion [Yahoo! Finance]
Low
Report
Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion [Yahoo! Finance]
12/18
07:19 pm
ibrx
ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain [Seeking Alpha]
Low
Report
ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain [Seeking Alpha]
12/16
04:37 pm
ibrx
ImmunityBio (NASDAQ:IBRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
09:00 am
ibrx
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
Medium
Report
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
12/14
03:09 am
ibrx
Should EMA's Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? [Yahoo! Finance]
Medium
Report
Should EMA's Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? [Yahoo! Finance]
12/13
07:33 am
ibrx
ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion [Yahoo! Finance]
Medium
Report
ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion [Yahoo! Finance]
12/12
12:03 pm
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/12
10:47 am
ibrx
ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week [Seeking Alpha]
Low
Report
ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week [Seeking Alpha]
12/12
06:53 am
ibrx
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe [Yahoo! Finance]
Medium
Report
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe [Yahoo! Finance]
12/12
06:10 am
ibrx
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
Medium
Report
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
12/11
08:07 am
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Medium
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
12/5
03:16 pm
ibrx
ImmunityBio, Inc. (IBRX): A Bull Case Theory [Yahoo! Finance]
Low
Report
ImmunityBio, Inc. (IBRX): A Bull Case Theory [Yahoo! Finance]
12/3
11:26 am
ibrx
ImmunityBio (IBRX) Slashes 9% on Lack of Leads [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Slashes 9% on Lack of Leads [Yahoo! Finance]
12/3
05:01 am
ibrx
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]
Medium
Report
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]
12/1
02:37 pm
ibrx
A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally [Yahoo! Finance]
Low
Report
A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally [Yahoo! Finance]
12/1
09:22 am
ibrx
ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences [Yahoo! Finance]
Medium
Report
ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences [Yahoo! Finance]
11/30
05:43 am
ibrx
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? [Yahoo! Finance]
Medium
Report
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? [Yahoo! Finance]
11/25
05:48 pm
ibrx
H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue [Yahoo! Finance]
Low
Report
H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue [Yahoo! Finance]
11/19
12:56 pm
ibrx
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know [Yahoo! Finance]
Low
Report
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know [Yahoo! Finance]
11/19
05:18 am
ibrx
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech [Seeking Alpha]
Low
Report
ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech [Seeking Alpha]
11/13
01:39 pm
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
11/13
12:18 pm
ibrx
How ImmunityBio's (IBRX) Revenue Surge and Narrowed Losses May Affect Investor Outlook [Yahoo! Finance]
Low
Report
How ImmunityBio's (IBRX) Revenue Surge and Narrowed Losses May Affect Investor Outlook [Yahoo! Finance]
11/13
09:36 am
ibrx
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations [Yahoo! Finance]
Low
Report
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations [Yahoo! Finance]
11/13
09:00 am
ibrx
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
Medium
Report
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
11/12
09:56 am
ibrx
enGene Holdings: Still A Buy After A Massive Surge [Seeking Alpha]
Low
Report
enGene Holdings: Still A Buy After A Massive Surge [Seeking Alpha]